Karim De felipe

Citi Investment Research & Analysis analysts Yaron Werber, Navdeep Singh and Karim De felipe maintained their Buy/Medium Risk rating for shares of Amgen Inc (Nasdaq: AMGN), with a price target of $64 per share. The analysts said that most regulatory hurdles for Amgen Inc's Dmab have been...